Specific activation of cGAS-STING pathway by nanotherapeutics-mediated ferroptosis evoked endogenous signaling for boosting systemic tumor immunotherapy

Sci Bull (Beijing). 2023 Mar 30;68(6):622-636. doi: 10.1016/j.scib.2023.02.027. Epub 2023 Feb 23.

Abstract

Activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway could effectively initiate antitumor immunity, but specific activation of STING pathway is still an enormous challenge. Herein, a ferroptosis-induced mitochondrial DNA (mtDNA)-guided tumor immunotherapy nanoplatform (designated as HBMn-FA) was elaborately developed for activating and boosting STING-based immunotherapy. On the one hand, the high-levels of reactive oxygen species (ROS) in tumor cells induced by HBMn-FA-mediated ferroptosis elicited mitochondrial stress to cause the release of endogenous signaling mtDNA, which specifically initiate cGAS-STING pathway with the cooperation of Mn2+. On the other hand, the tumor-derived cytosolic double-stranded DNA (dsDNA) from debris of death cells caused by HBMn-FA further activated the cGAS-STING pathway in antigen-presenting cells (e.g., DCs). This bridging of ferroptosis and cGAS-STING pathway could expeditiously prime systemic antitumor immunity and enhance the therapeutic efficacy of checkpoint blockade to suppress tumor growth in both localized and metastatic tumor models. The designed nanotherapeutic platform paves the way for novel tumor immunotherapy strategies that are based on specific activation of STING pathway.

Keywords: Ferroptosis; Nanotherapeutics; Tumor immunotherapy; cGAS-STING pathway; mtDNA release.

MeSH terms

  • DNA, Mitochondrial
  • Ferroptosis*
  • Humans
  • Immunotherapy
  • Interferon Type I* / metabolism
  • Neoplasms* / therapy
  • Nucleotidyltransferases / genetics

Substances

  • DNA, Mitochondrial
  • Interferon Type I
  • Nucleotidyltransferases
  • STING1 protein, human
  • cGAS protein, human